A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Official Title

A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma


The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.

Trial Description

Primary Outcome:

  • Incidence and Adverse Events (AEs) at its worst grade
  • Incidence of Serious Adverse Events (SAEs) at its worst grade
  • Incidence of AEs leading to discontinuations
  • Incidence of AEs leading to death
  • Frequency of laboratory test toxicity grade shifting from baseline
Secondary Outcome:
  • Best overall response (BOR)
  • Overall response rate (ORR)
  • Duration of response (DOR)
  • Progression free survival (PFS)
  • Changes in Fridericia-corrected QT interval (ΔQTcF)
  • Frequency of different subject immunogenicity status
  • Cmax (maximum observed serum and/or plasma concentration)
  • Tmax (time of maximum observed serum and/or plasma concentration)
  • AUC(0-t) (area under the concentration-time curve from time 0 to time t)
  • AUC(TAU) (area under the concentration-time curve in 1 dosing interval)
  • Ctau (concentration at the end of a dosing interval)
  • Ctrough (trough observed serum and/or plasma concentration, including predose concentrations and Ctau concentrations)
  • CLT (total body clearance calculated as dose divided by AUC(TAU)
  • Vss (apparent volume of distribution at steady-state)
  • Vz (volume of distribution of terminal phase)
  • AI_Cmax (accumulation index; ratio of Cmax at steady-state to Cmax after the first dose)
  • AI_Ctau (accumulation index; ratio of Ctau at steady-state to Ctau after the first dose)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society